Status:
NOT_YET_RECRUITING
Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Conditions:
Mantle Cell Lymphoma
Eligibility:
All Genders
60+ years
Phase:
PHASE2
Brief Summary
This is a single-arm, multi-center, prospective, phase II study. The primary objective is to assess the efficacy and safety of bendamustine/orelabrutinib combined with an anti-CD20 monoclonal antibody...
Detailed Description
Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin's lymphoma and is considered to be incurable. MCL patients have varied clinical presentations (generally symptomatic to an asymptomatic in...
Eligibility Criteria
Inclusion
- Gender not limited, aged ≥65 years, or aged ≥60 years but \<65 years and unsuitable or unwilling to undergo stem cell transplantation due to the following reasons:
- Creatinine clearance rate \>30 mL/min, but \<70 mL/min;
- Presence of other comorbidities that contraindicate high-intensity induction chemotherapy;
- High-risk patients who are expected to fail stem cell mobilization and collection (such as those with bone marrow infiltration, diabetes, thrombocytopenia). Patients who are unwilling to receive autologous stem cell transplantation, considering potential complications post-transplantation (such as prolonged bleeding, immunodeficiency, hemorrhage, severe infections), and relapse.
- Histologically confirmed mantle cell lymphoma at stages II-IV;
- Patients who have not received prior treatment;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;
- Adequate organ function:
- Hematological: Absolute neutrophil count ≥1.5×109/L, platelets ≥75×109/L, hemoglobin ≥75 g/L. If accompanied by bone marrow involvement: Absolute neutrophil count ≥1.0×109/L, platelets ≥50×109/L, hemoglobin ≥50 g/L.
- Biochemical: Total bilirubin ≤1.5 times the upper limit of normal (ULN), aspartate transaminase (AST) or alanine transaminase (ALT) ≤2 times ULN.
- Coagulation function: International normalized ratio (INR) ≤1.5 times ULN;
- Expected survival time ≥12 months;
- Voluntarily sign a written informed consent form before the trial screening.
Exclusion
- Progression to higher-grade disease or central nervous system involvement;
- Uncontrolled or significant cardiovascular diseases:
- Within 6 months prior to the first administration of the study drug, there was New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina pectoris, myocardial infarction, or a need for treatment of arrhythmia at the time of screening, with left ventricular ejection fraction (LVEF) \< 50%;
- Primary cardiomyopathies (such as dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, and unclassified cardiomyopathy);
- A history of clinically significant QTc interval prolongation, or a QTc interval \>470 ms for females or \>450 ms for males during the screening period;
- Participants with symptomatic or medication-requiring coronary artery disease;
- Participants with uncontrolled hypertension, defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg despite adequate therapy with three antihypertensive agents (including a diuretic) for at least one month, or requiring four or more antihypertensive agents to achieve control.
- Participants with active bleeding within 2 months prior to screening, those currently on anticoagulant therapy, or those deemed by the investigator to have a significant risk of bleeding;
- History of deep vein thrombosis or pulmonary embolism within the past 6 months;
- Major surgery within 6 weeks prior to screening or minor surgery within 2 weeks prior to screening. Major surgery is defined as any surgical procedure requiring general anesthesia; diagnostic endoscopy is not considered major surgery;
- Active infection or uncontrolled hepatitis B virus (HBV) infection (HBsAg positive and/or HBcAb positive with detectable HBV DNA), hepatitis C virus (HCV) antibody positive, HIV/AIDS, or other severe infectious diseases;
- Participants with pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation-induced lung disease, drug-related lung disease, or other conditions affecting pulmonary function;
- Pregnant women, breastfeeding women, and fertile participants unwilling to use effective contraception;
- Participants requiring continuous use of drugs with strong inhibition or induction effects on cytochrome P450 CYP3A4;
- Other conditions deemed unsuitable for participation in this trial by the investigator.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT07206264
Start Date
October 1 2025
End Date
December 1 2028
Last Update
October 3 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
2
Hebei Medical University Tumor Hospital
Shijiazhuang, Hebei, China
3
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
4
Shandong Cancer Hospital
Jinan, Shandong, China